Protara's TARA-002 Shows Durable Bladder Cancer Response at 12 Months

NEW YORK, NY – May 15, 2026 – Protara Therapeutics has unveiled promising new data for its investigational bladder cancer therapy, TARA-002, signaling a potential paradigm shift for patients with non-muscle invasive bladder cancer (NMIBC). The updated 12-month results from the ongoing Phase 2 ADVANCED-2 trial, presented today at the American Urological Association (AUA) 2026 Annual Meeting, demonstrate both durable efficacy and a strong safety profile in patients who have not previously received the standard-of-care treatment, Bacillus Calmette-Guérin (BCG).

According to the announcement, TARA-002 achieved a 55% complete response (CR) rate at the 12-month mark in this BCG-naïve patient group. The therapy showed even higher response rates at earlier time points, with a 66.7% CR rate at six months and an impressive 72.4% CR rate at any time during the evaluation. Crucially, the treatment was well-tolerated, with no Grade 3 or greater treatment-related adverse events reported, a significant finding in a field where harsh side effects can often lead to treatment discontinuation.

“Today’s presentation demonstrates TARA-002’s impressive 12-month durability data and excellent safety profile for patients with BCG-Naïve NMIBC,” said Dr. Mark Tyson, a study investigator and Professor of Urology at Mayo Clinic Phoenix. “These compelling data, coupled with a simple, streamlined administration for both physicians and patients, make TARA-002 a potentially important new treatment option for BCG-Naïve high risk NMIBC patients.”

Addressing a Critical Void in Cancer Care

Non-muscle invasive bladder cancer is the most common form of bladder cancer, accounting for approximately 80% of new diagnoses, or about 65,000 new patients in the United States each year. The standard treatment for high-risk NMIBC for decades has been intravesical BCG, an immunotherapy that stimulates a local immune response in the bladder. While effective for many, BCG therapy is not a panacea. Between 30% and 50% of patients either do not respond to the treatment or see their cancer return. Furthermore, the therapy is associated with significant side effects, including urinary distress and flu-like symptoms, which lead up to 9% of patients to stop treatment.

Compounding these clinical challenges are persistent, worldwide shortages of BCG, which have forced clinicians to ration supplies and seek alternative, often less effective, treatments. For patients who fail BCG therapy, the next step is often a radical cystectomy—the complete surgical removal of the bladder. This is a life-altering procedure with major impacts on a patient's quality of life, underscoring the urgent, unmet need for effective, bladder-sparing alternatives.

Protara’s TARA-002 aims to fill this void. The data suggest it could provide a powerful new option for patients at the outset of their treatment journey, potentially avoiding the pitfalls of BCG altogether.

A Novel Mechanism in a Competitive Field

TARA-002 is an investigational cell therapy derived from an inactivated strain of Streptococcus pyogenes. It works as a novel immunopotentiator, activating key immune pathways—specifically TLR2 and NOD2—to marshal both the innate and adaptive immune systems against cancer cells within the bladder wall. This mechanism not only triggers a pro-inflammatory response that attacks the tumor but is also hypothesized to directly kill cancer cells.

Interestingly, TARA-002 was developed from the same master cell bank as OK-432 (Picibanil®), a broad immunopotentiator that has been successfully marketed in Japan for decades, lending a strong scientific legacy to Protara's candidate. The approach represents a new frontier in immunotherapy, moving beyond the well-trodden path of checkpoint inhibitors to harness a different aspect of the body's natural defenses.

The NMIBC treatment landscape is a hotbed of innovation, with a market projected to grow from around $2.9 billion in 2024 to over $14 billion by 2035. Numerous companies are vying to develop the next standard of care. Janssen's TAR-200, an intravesical drug-delivery system, is in a Phase 3 trial for BCG-naïve patients. Major pharmaceutical players like AstraZeneca and Pfizer are also testing their blockbuster checkpoint inhibitors in combination with BCG. Against this backdrop, TARA-002's 55% complete response rate at 12 months, combined with its favorable safety, positions it as a highly competitive monotherapy candidate.

The Path to Market

Bolstered by these strong Phase 2 results, Protara Therapeutics is charting a clear path toward commercialization. The company confirmed it remains on track to initiate a pivotal Phase 3 registrational trial, ADVANCED-3, in the second half of 2026. This trial will compare TARA-002 directly against intravesical chemotherapy in BCG-naïve and potentially BCG-exposed patients. A successful outcome in a registrational trial is the final step required before seeking marketing approval from regulatory bodies like the FDA.

“These data continue to support our conviction that TARA-002 has the potential to make a meaningful difference in the lives of patients with BCG-Naïve NMIBC,” stated Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “Notably, the durable 12-month complete response rate observed... continues to perform competitively among approved treatments and investigational therapies in development.”

Investors have taken notice of the company's progress. Protara, which currently holds a market capitalization of around $290 million, has received a “Moderate Buy” consensus from market analysts, with some price targets suggesting a potential upside of over 300%. The FDA has already granted TARA-002 multiple designations, including Breakthrough Therapy and Fast Track, which can help expedite its development and review timeline. As Protara prepares for its pivotal study, the journey of TARA-002 will be a closely watched narrative for patients, clinicians, and investors alike.